Evaluation of the effectiveness of Deuterium depleted Water (DDW) in type 2 diabetes treatment.

Evaluation of the effect of Deuterium depleted Water (DDW) on glucose level, Insulin level, lipid profile, and parameters involved in regulation of antioxidant activity of type 2 diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210724051969N1

Enrollment

Registered

2021-11-15

Start date

2021-08-23

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes type II. Type II diabetes (insulin independent diabetes)

Interventions

Intervention 1: Intervention group: This group will be receive and use 1.5 liters of deuterium depleted water with 80 ppm deuterium concentration daily. This will be the patients source of daily drink

Eligibility

Sex/Gender

All

Age

27 Years to 77 Years

Inclusion criteria

Inclusion criteria: Patients must give their written consent to join the study voluntarily and knowingly. Patients must be diagnosed with type II diabetes with HbA1c levels between 6.5 to 7.5%. Patients must be under oral treatment with common medications to treat diabetes, such as sulfonyl urea, methformin, DPP4 inhibitors, SGLT2 inhibitors, pioglytazone. No history of autoimmune disorders. Patients must not have compromised cognitive ability. Patients may not be in any stage of pregnancy or lactation. Patients must be between 27-77 years of age.

Exclusion criteria

Exclusion criteria: Lack of a knowing and voluntary patient consent in written form. unwillingness to continue the study. Unwillingness to adhere to the project's protocols. Decision of the medical staff for any unforeseen reasons.

Design outcomes

Primary

Measure	Time frame
Fasting Blood Sugar. Fasting blood sugar is generally above 125 mg/dL in type II diabetes patients. Timepoint: At the beginning of the study and 90 days after use of regular water or deuterium depleted water. Method of measurement: Blood test for fasting blood sugar.;Glycated hemoglobin, (HbA1c). Timepoint: At the beginning of the study and 90 days after use of regular water or deuterium depleted water. Method of measurement: Testing glycated hemoglobin in the blood. Glycated hemoglobin levels in type II diabetes patients is generally above 6.5%.	—

Measure

Time frame

Fasting Blood Sugar. Fasting blood sugar is generally above 125 mg/dL in type II diabetes patients. Timepoint: At the beginning of the study and 90 days after use of regular water or deuterium depleted water. Method of measurement: Blood test for fasting blood sugar.;Glycated hemoglobin, (HbA1c). Timepoint: At the beginning of the study and 90 days after use of regular water or deuterium depleted water. Method of measurement: Testing glycated hemoglobin in the blood. Glycated hemoglobin levels in type II diabetes patients is generally above 6.5%.

—

Secondary

Measure	Time frame
Antioxidant effects. Timepoint: At the beginning of the study and 90 days after use of regular water or deuterium depleted water. Method of measurement: Tests for malondialdehyde, catalase, glutathione peroxidase, glutathione, superoxide dismutase, and total antioxidant capacity.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Faezeh Fatemi

Atomic Energy Organization of Iran

fatemi81@yahoo.com+98 21 8206 8222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026